Partnership discussions are already underway, but make no mistake—we are also advancing our commercial plan to launch KETARx™ this year. We have a clear and scalable sales channel targeting hospitals, specialty clinics, government institutions such as the U.S. Department of Defense and Veterans Health Administration, as well as clinical research programs and support for special or expanded access programs. And this is only Phase One. Millions of surgical patients stand to benefit today, but the long-term po ...

PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM)) August 14, 2025 8:00 AM EDT | Source: PharmaTher Holdings Ltd. Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has ...